Posted by Michael Wonder on 31 May 2022
FDA accepts Dupixent (dupilumab) for priority review in adults with prurigo nodularis
31 May 2022 - Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved.
The U.S. FDA has accepted for priority review the supplemental biologics license application for Dupixent (dupilumab) to treat adults with prurigo nodularis, a chronic inflammatory skin disease that causes extreme itch and skin lesions.
The target action date for the FDA decision is 30 September 2022.
